Lineage Cell Therapeutics, Inc.
AMEX:LCTXBiotechnology
-$0.04 today
- Market cap
- $212.10M
- Beta
- 1.51
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 1.22M
Average 1.19M
Income Statement
Follow revenue through to earnings.
Revenue
$14.56M
FY 2025 · Annual
+53.2% YoYOperating Income
-$21.78M
FY 2025 · Annual
Net Income
-$63.53M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.9M | 14.7M | 8.95M | 9.5M | 14.56M |
| Cost of Revenue | 1.43M | 728K | 671K | 334K | 845K |
| Gross Profit | 2.47M | 13.98M | 8.27M | 9.17M | 13.71M |
| Gross Margin | 63.4% | 95.0% | 92.5% | 96.5% | 94.2% |
| Research & Development | 33.91M | 13.99M | 15.71M | 12.47M | 17.73M |
| Selling, General & Admin | 18.21M | 22.51M | 17.3M | 18.17M | 18.46M |
| Operating Expenses | 51.68M | 36.5M | 33.01M | 30.64M | 35.49M |
| Depreciation & Amortization | 873K | 727K | 692K | 609K | 699K |
| EBITDA | (42.4M) | (25.09M) | (22.59M) | (17.97M) | (67.95M) |
| EBITDA Margin | -1088.2% | -170.6% | -252.5% | -189.2% | -466.8% |
| Operating Income | (49.21M) | (22.52M) | (24.73M) | (21.48M) | (21.78M) |
| Operating Margin | -1263.1% | -153.2% | -276.5% | -226.1% | -149.6% |
| Interest Income | 2K | 829K | 1.63M | 1.72M | 1.69M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.94M | (3.29M) | 1.45M | 2.9M | (46.87M) |
| Income Before Tax | (43.27M) | (25.81M) | (23.28M) | (18.58M) | (68.65M) |
| Pre-Tax Margin | -1110.6% | -175.6% | -260.3% | -195.6% | -471.6% |
| Income Tax Expense | 0 | 541K | (1.8M) | 0 | (5.11M) |
| Net Income | (43.02M) | (26.27M) | (21.49M) | (18.61M) | (63.53M) |
| Net Margin | -1104.2% | -178.7% | -240.2% | -195.9% | -436.5% |
| EPS (Basic) | (0.26) | (0.15) | (0.12) | (0.09) | (0.28) |
| EPS (Diluted) | (0.26) | (0.15) | (0.12) | (0.09) | (0.28) |
| 164.5M | 169.79M | 172.66M | 200.19M | 230.12M | |
| 164.5M | 169.79M | 172.66M | 200.19M | 230.12M |
LCTX Earnings Waterfall · TTM
AMEX:LCTX · Revenue to Net Income
Key Ratios
Analysis
$14.8M of revenue converted into -$64.2M of net income for the selected period. Gross margin is 96.6% and net margin is -544.2%, showing how much revenue survives after costs and taxes. EPS is $-0.28, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Aug 6, 2026 | |
| 8-K | Current report | Aug 6, 2026 | |
| SC 13G | SC 13G filing | Jul 29, 2026 |
How much revenue does LCTX generate?
Lineage Cell Therapeutics, Inc. (LCTX) reported $14.56M of revenue in fiscal 2025.
Is LCTX profitable?
Lineage Cell Therapeutics, Inc. (LCTX) reported -$63.53M of net income, with a net margin of -436.5%.
Continue the stock analysis
Jump to another research area for this company.